Merck & Co defends Fosamax over safety claims
This article was originally published in Scrip
Merck and Co's leading oral bisphosphonate for the treatment of osteoporosis, Fosamax (alendronate), has been linked to incidents of oesophageal cancer and jaw necrosis in two separate studies published in the New England Journal of Medicineand the Journal of the American Dental Association (JADA), respectively, but Merck hasvigorously defended the drug's safety profile, which had sales of $3.1 billion in 2007 before its patent expired last year.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.